2nd Quarter 2025 Financial Results & Corporate Update August 4th, 2025 Exhibit 99.2

2 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech’s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech’s expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; discussions with regulatory agencies; BioNTech’s expectations with respect to intellectual property; the impact of BioNTech’s collaboration and licensing agreements, including BioNTech’s partnership with BMS; BioNTech’s planned acquisition of CureVac; the development, nature and feasibility of sustainable vaccine production and supply solutions; the deployment of AI across BioNTech’s preclinical and clinical operations; BioNTech's expectations with respect to tariff policy; BioNTech’s estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities; BioNTech's expectations regarding upcoming payments relating to litigation settlements; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech’s expectations of net profit / (loss). In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward- looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech’s pricing and coverage negotiations regarding its COVID-19 vaccine with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech’s other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech’s COVID- 19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech’s and its counterparties’ ability to manage and source necessary energy resources; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of COVID-19 on BioNTech’s development programs, supply chain, collaborators and financial performance; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market BioNTech’s COVID-19 vaccine and, if approved, its product candidates; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2025, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. Furthermore, certain statements contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and BioNTech’s own internal estimates and research. While BioNTech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, any market data included in this presentation involves assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. While BioNTech believes its own internal research is reliable, such research has not been verified by any independent source. In addition, BioNTech is the owner of various trademarks, trade names and service marks that may appear in this presentation. Certain other trademarks, trade names and service marks appearing in this presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this presentation may be referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. An abbreviation directory of defined terms can be found at the end of the presentation.

Strategic Outlook Ryan Richardson, Chief Strategy Officer 3 Financial Update Ramón Zapata, Chief Financial Officer 4 Oncology Pipeline Update Özlem Türeci, Co-founder & Chief Medical Officer2 2nd Quarter 2025 Update Ugur Sahin, Co-founder & Chief Executive Officer1

1 2nd Quarter 2025 Update Ugur Sahin, Co-founder & Chief Executive Officer

Building a Global Immunotherapy Powerhouse Translating Science into Survival

6 Partnered with: 1. Genentech, a member of the Roche Group; 2. Bristol Myers Squibb. Our Priorities are Our Novel mRNA Cancer Immunotherapies and Our Next-Generation IO-Backbone PD-L1/VEGF-A antibody BNT3272 Novel mRNA cancer immunotherapies Potential to become the next-generation IO-backboneNext-generation of personalized cancer therapy targeting tumor associated antigens and cancer mutations FixVac & iNeST1 Our next-generation IO-backbone Resected cancers (adjuvant) Neoadjuvant, 1L advanced/metastatic Late stage, refractory cancers Clinical-stage candidates for combination therapy IO molecules mRNA immunotherapies ADCs

Q2 2025+ Progress Towards Our Strategic Goals 7 BNT3271 • Preparing for global commercial roll-out of new variant-adapted COVID-19 vaccine3 Additional corporate updates • Expanded partnership with UK Government to broaden regional R&D activities with plans to invest up to £1 bn over the next decade mRNA cancer immunotherapies Execution in oncology COVID-19 leadership • Announced planned strategic transaction to acquire CureVac in public exchange offer • Achieved FPD in cohort evaluating BNT116 in combination with B7-H3 ADC BNT324/DB-13112 • Progressing broad pan-tumor development plan spearheaded by Phase 3 trials in lung and breast cancer • Announced global strategic partnership with BMS to co-develop and co-commercialize BNT3271 • Achieved FPD in trials evaluating the combination with HER2 ADC BNT323/DB-13032 and B7-H3 ADC BNT324/DB-13112 Partnered with 1. Bristol Myers Squibb; 2. DualityBio; 3. Pfizer, pending approvals from the relevant health authorities; 4. Cash and cash equivalents plus security investments as of June 30, 2025, reached €15,989.3 million, comprising €10,269.5 million in cash and cash equivalents, €3,363.8 million in current security investments and €2,356.0 million in non-current security investments. Strategic R&D partnership Financials COMIRNATY • Strong balance sheet with ~€16.0 bn total cash and cash equivalents plus security investments4

8 BioNTech and BMS Enter Landmark Strategic Collaboration to Advance BNT3271 Potential to transform standard of care and establish new IO backbone treatment option for patients with high unmet medical needs Maximizing potential of next-generation immunomodulator BNT3271 with global co-development and co-commercialization partnership • Bispecific antibody targeting PD-L1 and VEGF-A • Over 1,200 patients treated in clinical trials across multiple tumor types • Broad development ongoing in 10+ indications, including initial registrational trials Anti-VEGF-A Anti-PD-L1 VHH 1. Partnered with Bristol Myers Squibb.

9 Harnessing Complementary Expertise to Maximize BNT3271 Potential 1. Partnered with Bristol Myers Squibb. Patient-centric scientific excellence United in oncology combination strategy Operational execution & speed to market Manufacturing scalability Commercial presence ➢ Unique pipeline enabling multiple potential BNT3271 combinations for solid tumors (e.g., ADCs, mRNA) ➢ BNT3271: Studied in 10+ indications, 20+ trials, 3 ongoing or planned global registrational trials ➢ Building global commercial capabilities including U.S. and non-U.S. key markets ➢ Global clinical development expertise in novel and combination therapies; 3 approved IO assets ➢ 30+ U.S. FDA approvals since 2015; 20+ potential NMEs in oncology pipeline ➢ Top-tier, global market leader with preeminent commercial capabilities and infrastructure

2 Oncology Pipeline Update Özlem Türeci, Co-founder & Chief Medical Officer

Advancing Towards Commercial Stage in Oncology Partnered with: 1. Bristol Myers Squibb; 2. DualityBio 11 BNT3271 BNT323/DB-13032 mRNA Cancer Immunotherapies Aim to accelerate and expand BNT3271 development with strategic BMS collaboration mRNA cancer immunotherapy data expected in late 2025 or early 2026 Advance BNT323/DB-13032 towards BLA submission in EC and BC

BNT3271 Synergistic Targeting of PD-L1 and VEGF Local neutralization of angiogenic and immunosuppressive VEGF-A effects NSCLC IHC2 Bispecific MOA 1. Partnered with Bristol Myers Squibb; 2. IHC data: Human Protein Atlas VEGF-A PD-L1 Targeting the TME and blockade of PD-1/PD-L1 signaling Anti-VEGF-A (Fab) Anti-PD-L1 (VHH) VEGF-A dimer in the TME PD-L1 ligand on tumor cells Tumor microenvironment (TME) BNT327 VEGF-A dimer in the TME Anti-VEGF-A (Fab) Anti-PD-L1 (VHH) PD-L1 ligand on tumor cells 12

13 Partnered with: 1. Bristol Myers Squibb Accelerating and Broadening BNT3271 Global Clinical Development Exploring the potential of BNT3271 in three waves of focused development 3 Broaden2 Combine1 Establish BNT3271 + ADC: Explore expansion to novel combinations with ADCs in high unmet need indications BNT3271 + novel assets: Broaden to further indications • Two Phase 2 dose optimization trials ongoing in TNBC and SCLC with data in 2025 • Phase 3 trial ongoing in SCLC (ROSETTA Lung-01) • Phase 2/3 trial ongoing in NSCLC (ROSETTA Lung-02) • Phase 3 trial planned in TNBC (ROSETTA Breast-01) • Three Phase 1/2 and one Phase 2 combination trials with three novel ADCs ongoing • Phase 1/2 combination trial with a fourth novel ADC planned BNT3271 + chemo: Establish in combination with chemo in key indications with fast-to-market potential

Establish: BNT3271 Combined With Chemotherapy Indicated Encouraging Efficacy in 1L ES-SCLC in Phase 2 Study 1. Partnered with: 1. Bristol Myers Squibb; 2. Incidence from: SEER data for diagnosed SCLC incidence in U.S.; Cancer Research UK; Zentrum für Krebsregisterdaten; Sante Publique; AIOM; EPDATA. 3. Benchmark study: IMpower133 as reported in L. Horn et al., New England Journal of Medicine, 2018 4. The above information is not based on head-to-head trials between BioNTech’s investigational candidates and other products or product candidates. Furthermore, definitive conclusions cannot be drawn from cross-trial comparisons or anticipated data, as they may be confounded by various factors, and should be interpreted with caution. Unmet medical need remains high for patients with ES-SCLC Patients with ES-SCLC2 have a 5-year survival rate of 3% We believe BNT327 has the potential to become a new first-line treatment option for patients with ES-SCLC3 Benchmark3 comparator data (IMpower133) L. Horn et al., New England Journal of Medicine, 2018 1L ES-SCLC Benchmark regimen Atezo + Chemo ORR 60% Median PFS 5.2 months Median OS 12.3 months The above data are not based on a head-to-head study comparing BioNTech’s investigational products with other products/candidates - no conclusions can be drawn.4 Phase 2 Study (NCT05844150)​: Emerging efficacy profile Ying Cheng et al. presented at ELCC 2025 ITT population (n=48)​ Confirmed ORR (95% CI) 85.4 % (72.2, 93.9) Median PFS (95% CI) 6.9 months (4.34, 8.21) Median OS (95% CI) OS events, n (%) 16.8 months (14.3, --)​ 17 (35.4) 12-month OS rate (95% CI) 72.7 % (57.6, 83.1)​ A manageable safety profile was observed, with no new safety signals beyond those typically described for chemotherapy agents and anti-PD-(L)1 and anti-VEGF monotherapies. 14 Global Phase 3 study ongoing (ROSETTA Lung-01)

Establish: BNT3271 Monotherapy Efficacy in 1L NSCLC 15 1. Partnered with Bristol Myers Squibb; 2. Reck, M. et al., New England Journal of Medicine, 2016. Phase 1b/2a (NCT05918445): cohort 1, 1L NSCLC (EGFR & ALK WT) Wu, C. et al. presented at ASCO 2024. Poster #8533. 1L NSCLC mono treatment (cohort 1, n=17): ORR 47%, DCR 100%, mPFS 13.6 months Comparable ORR in PD-L1 1–49% (n=9) and PD-L1 ≥50% (n=8) Waterfall/spider plots and Kaplan-Meier curves (PFS) PD-L1 ≥50% PD-L1 1–49% SD PR 60 40 20 0 −20 −40 −60 −80 B e s t c h a n g e f ro m b a s e lin e ( % ) 0 50 SD PD PR On Treatment 30 10 −10 −30 −50 −70 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 C h a n g e f ro m b a s e lin e ( % ) Months Data Cut of Date: 2024-03-15 Indication Benchmark regimen ORR mPFS mOS Benchmark study 1L NSCLC (PD-L1 > 50%) Pembro monotherapy 45% 7.7 mo 26.3 mo KEYNOTE-0242 Global Phase 2/3 study ongoing (ROSETTA Lung-02)

Establish: BNT3271 Combined With Chemotherapy Indicated Encouraging Efficacy in 1L TNBC Irrespective of PD-L1 Status in Phase 1/2 Study 1. Partnered with Bristol Myers Squibb; 2. Incidence from SEER (U.S.); Zentrum für Krebsregisterdaten (DE); Globocan (ES); Sante Publique (FR); AIOM (IT); Cancer Research UK . 3 Benchmark study: KEYNOTE-355 as reported in Cortes, J, et al. New England Journal of Medicine, 2022. 4. The above information is not based on head-to-head trials between BioNTech’s investigational candidates and other products or product candidates. Furthermore, definitive conclusions cannot be drawn from cross-trial comparisons or anticipated data, as they may be confounded by various factors, and should be interpreted with caution. 5. Obtained from subgroup analysis. 6. mPFS for CPS < 10 subgroup from Cortes, J. et al. Lancet, 2020. Unmet medical need remains high for patients with TNBC Patients with Stage IV TNBC2 have a 5-year survival rate of 10% We believe BNT327 has the potential to become a first-line treatment option for patients with TNBC3, including those currently not addressed by existing IO therapies Benchmark3 comparator data by PD-L1 expression level (Keynote-355) Cortes, J, et al., New England Journal of Medicine, 2022 1L TNBC (CPS <10)5,6 1L TNBC (CPS ≥ 10) Benchmark regimen Chemo Pembro + Chemo ORR 35 % 53 % Median PFS 5.7 months 9.7 months Median OS 15.2 months 23.0 months The above data are not based on a head-to-head study comparing BioNTech’s investigational products with other products/candidates - no conclusions can be drawn.4 Phase 1/2 Study (NCT05918133)​: Interim overall survival Jiong Wu et al. presented at SABCS 2024 ITT population (n=42)​ Confirmed ORR (95% CI) 73.8 % (58.0, 86.1) Median PFS (95% CI) 13.5 months (9.4, 19.3) 12-month OS rate (95% CI) 80.8 % (65.3, 89.9)​ 18-month OS rate (95% CI) 69.7 % (52.7, 81.6)​ A manageable safety profile was observed, with no new safety signals beyond those typically described for nab-paclitaxel and anti-PD-1/PD-L1 and anti-VEGF monotherapies.​ 16 Global Phase 3 planned for 2025 (ROSETTA Breast-01)

17 Partnered with: 1. Bristol Myers Squibb; 2. DualityBio; 3. MediLink. Accelerating and Broadening BNT3271 Global Clinical Development Exploring the potential of BNT3271 in three waves of focused development Ongoing • Phase 2 in TNBC • Phase 2 in SCLC • Phase 3 in SCLC (ROSETTA Lung-01) • Phase 2/3 in NSCLC (ROSETTA Lung-02) Planned • Phase 3 in TNBC (ROSETTA Breast-01) for 2025 3 Broaden2 Combine1 Establish BNT3271 + chemo: Establish in combination with chemo in key indications with fast-to-market potential BNT3271 + novel assets: Broaden to further indications Planned • Phase 1/2 with BNT326/YL2023(HER3) Ongoing • Phase 1/2 with BNT325/DB-13052 (TROP2) in solid tumors • Phase 1/2 with BNT323/DB-13032 (HER2) in advanced breast cancer • Phase 1/2 with BNT324/DB-13112(B7-H3) in advanced lung cancer • Phase 2 with BNT324/DB-13112 (B7-H3) in advanced solid tumors Diverse portfolio of clinical oncology assets in-house • Combine with novel IO bispecifics • Combine with novel ADCs • Evaluate additional indications in partnership with BMS BNT3271 + ADC: Explore expansion to novel/novel combinations with ADCs in high unmet need indications

Preliminary data combining BNT3271 with BNT325/DB-13052 showed a manageable safety profile with few overlapping toxicities​ and signs of clinical activity 18 1. Partnered with: 1. Bristol Myers Squibb; 2.Duality. Combine: BNT3271 with Novel ADCs in High Unmet Need Indications 20% 0 –20 –40 –60 –80 –100B e s t c h a n g e f ro m b a s e li n e i n s u m o f ta rg e t le s io n d ia m e te rs ( % ) –30% 20 40 Three Phase 1/2 and one Phase 2 combination trials with three novel ADCs ongoing Combination with an additional novel ADC planned to start in 2025 Phase 1/2 (NCT05438329): BNT3271 combined with TROP2 ADC BNT325/DB-13052 in 2L–4L PROC Erika Hamilton et al. Presented at AACR 2025. Poster: 648 / 14 Waterfall plot for PROC from dose expansion cohort in 2-4L PROC (N=13)TRAEs occurring in ≥10% of patients receiving BNT325 + BNT3271 Q3W (N=67)

19 Partnered with: 1. Bristol Myers Squibb; 2. DualityBio; 3. MediLink; 4. In collaboration with Regeneron; 5. Genmab Accelerating and Broadening BNT3271 Global Clinical Development Exploring the potential of BNT3271 in three waves of focused development Ongoing • Phase 2 in TNBC • Phase 2 in SCLC • Phase 3 in SCLC (ROSETTA Lung-01) • Phase 2/3 in NSCLC (ROSETTA Lung-02) Planned • Phase 3 in TNBC (ROSETTA Breast-01) for 2025 3 Broaden2 Combine1 Establish BNT3271 + novel assets: Broaden to further indications Ongoing • Phase 1/2 with BNT325/DB- 13052 (TROP2) in solid tumors • Phase 1/2 with BNT323/DB- 13032 (HER2) in advanced breast cancer • Phase 1/2 with BNT324/DB- 13112 (B7-H3) in advanced lung cancer • Phase 2 with BNT324/DB- 13112 (B7-H3) in advanced solid tumors Planned • Phase 1/2 with BNT326/YL2023 (HER3) Diverse portfolio of clinical oncology assets in-house • Combine with novel IO bispecifics • Combine with novel ADCs • Evaluate additional indications in partnership with BMS Ongoing • Phase 1/2 trial ongoing in China to evaluate BNT3271 combination with TIGIT x PVRIG bsAb BNT3214 in HCC Planned • Phase 1/2 trial to evaluate BNT3271 combination with IO bispecific BNT314/GEN10595 and/or chemotherapy in CRC is expected to start in 2025

Leveraging Our Leadership in mRNA to Fully Exploit Cancer Immunotherapy Target Space with Two Approaches 20 1 Partnered with Genentech, a member of the Roche Group. 2 Antigens vary across programs; 3. T-cell responses analyzed by ex vivo multimer staining analysis in blood. Individual patient samples (blood and tissue) Artificial intelligence-driven neoantigen prediction On-demand tailored RNA manufacturing Individualized immuno- therapy Mapping of mutations Fixed combination of shared tumor antigens2 Multi-antigen approach tailored to each indication Neoantigens Individualized therapy Multiple shared antigens Off-the-shelf therapy iNeST1 FixVac individualized Neoantigen- Specific immunotherapy Fixed Antigen Vaccine ANTIGEN 1 ANTIGEN 2 ANTIGEN 3 ANTIGEN 4 Strong vaccine- induced, poly- epitope ex vivo CD8+ T-cell responses across different cancer types3 10.3% 10.1% HPV16-E7 Head & Neck Cancer BNT113, HARE40 trial Mutant Neoantigen TNBC, BNT114 TNBC-MERIT trial 5% MAGE-A3 Melanoma, BNT111, Lipo-MERIT trial 2.1% NY-ESO-1 Melanoma , BNT111, Lipo-MERIT trial mRNA- lipoplex platform Described in Castle et al., Cancer Res 2011 Described in Sahin et al., Nature 2017

Clinical Trial Execution Across iNeST and FixVac Portfolios 21 1. Partnered with Genentech, a member of the Roche Group; 2. In collaboration with Regeneron. Individualized immunotherapy: iNeST FixVac Autogene cevumeran (BNT122/RO7198457)1 BNT1112 BNT113 BNT116 Adjuvant 1L R/R R/R 1L Multiple settings MIUC Phase 2 CRC Phase 2 PDAC Phase 2 Melanoma Phase 2 Solid tumors Phase 1 Melanoma Phase 2 HPV16+ HNSCC Phase 2/3 NSCLC Phase 1 & 2 + Nivolumab Monotherapy + Atezolizumab + mFOLFIRINOX + Pembrolizumab + Atezolizumab + Cemiplimab + Pembrolizumab Monotherapy, + Cemiplimab or CTx or aCTLA4 Voluntary temporary hold Recruitment ongoing Data presented from epi sub- study at ASCO 2024 and from biomarker sub- study at ESMO- GI 2024 Recruitment ongoing Data from Phase 1 trial published in 2023 (Rojas et al., Nature) Follow up data published in February 2025 (Sethna et al., Nature) Trial completed (N=125) Primary endpoint (significant PFS improvement) not met. Numerical OS benefit trend observed. Data to be presented at ESMO 2025 Trial completed Data ​published (Lopez et al., Nature Medicine 2025) Enrollment completed (N=184) Positive topline data announced in 2024 Data to be presented at ESMO 2025 Recruitment ongoing Trial updated to Phase 2/3 Recruitment ongoing in Ph 2 in 1L NSCLC2 Data presented at AACR 2025 Data to be presented at WCLC 2025

3 Financial Update Ramón Zapata, Chief Financial Officer

Q2 and H1 Financial Results 23 1. Numbers have been rounded; numbers presented may not add up precisely to the totals and may have been adjusted in the table. Presentation of the consolidated statements of profit or loss has been condensed. More information can be found in BioNTech’s Report on Form 6-K for the three and six months ended June 30, 2025, filed today with the U.S. SEC. and available at https://www.sec.gov/; 2. Cash and cash equivalents plus security investments as of June 30, 2025, reached €15,989.3 million, comprising €10,269.5 million in cash and cash equivalents, €3,363.8 million in current security investments and €2,356.0 million in non-current security investments. (in millions €, except per share data)1 Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenues 261 129 444 316 Cost of Sales (76) (60) (160) (119) Research and Development Expenses (509) (585) (1,035) (1,092) Sales and Marketing Expenses (19.7) (12.9) (33.4) (28.5) General and Administrative Expenses (117.7) (170.9) (224.6) (287.9) Other Operating Result (39) (267) (26) (261) Operating Loss (501) (966) (1,035) (1,473) Finance Result 98 (160) 187 335 Income Taxes 16 (2) 46 15 Net Loss (387) (808) (802) (1,123) Basic and Diluted Loss per Share (1.60) (3.36) (3.33) (4.67) Balance Sheet as of June 30, 2025 – Cash and cash equivalents plus security investments2 €16.0 bn

BMS Partnership Aims to Strengthen Cash Position and P&L for Multiple Years1 24 1. These statements, including the anticipated timing of certain events, are based on BioNTech’s current expectations regarding the BMS collaboration and are subject to the successful co-development, approval and co-commercialization of BNT327. These statements are also based in part on assumptions and judgments that the Company has made, which may be subject to significant uncertainties. Although the Company’s approach to revenue recognition is based on facts and circumstances known to the Company and various other assumptions that the Company believes to be reasonable under the circumstances, the revenue assessment is ongoing, and its actual results may deviate from its current expectations. 2. Majority of milestone payments expected to be triggered upon approvals and during commercialization. 3. Revenue of initially constrained milestone payments may be recognized at the point of satisfaction or over time, including catch-up effects for prior periods as applicable. More information can be found in BioNTech’s Report on Form 6-K for the three and six months ended June 30, 2025, filed today, and in BioNTech’s Report on Form 20-F for the year ended December 31, 2024 filed on March 10, 2025, both of which are available at www.sec.gov. Payment Anticipated Cash Effect Anticipated Revenue Effect Upfront Cash Payment $1.5 bn Q3 2025 Revenue recognition over the development phase Non-Contingent Anniversary Cash Payments $2.0 bn 2026 - 2028 Revenue recognition over the development phase Development, Regulatory & Commercial Milestone Cash Payments2 up to $7.6 bn Cash payments would align to milestone timing Revenue recognition following milestone achievement3 Global profits and losses will be equally shared between BioNTech and BMS BioNTech and BMS will share joint development and manufacturing costs of BNT327 on a 50:50 basis subject to certain exceptions

2025 Financial Year Guidance Reaffirmed1 25 1. Excludes external risks that are not yet known and/or quantifiable, including, but not limited to, the effects of ongoing and/or future legal disputes and related activities, as well as certain potential one-time effects and charges related to portfolio prioritization. It includes effects identified from licensing arrangements, collaborations and M&A transactions to the extent disclosed and completed and may be subject to update. It excludes the effect of the announced transaction to acquire CureVac, which is ongoing. The Company does not expect to report a positive net income figure for the 2025 financial year. These statements are also based in part on assumptions and judgments that the Company has made, which may be subject to significant uncertainties. Although the Company’s approach to revenue recognition is based on facts and circumstances known to the Company and various other assumptions that the Company believes to be reasonable under the circumstances, the revenue assessment is ongoing, and its actual results may deviate from its current expectations. FY 2025 Guidance Planned FY 2025 revenues Revenues €1,700 – €2,200 m Planned FY 2025 expenses and capex R&D expenses €2,600 – €2,800 m SG&A expenses €650 – €750 m Capital expenditure for operating activities €250 – €350 m Guidance considerations Relatively stable pricing and market share as compared to 2024. Revenue phasing expected to be primarily concentrated in the last 3-4 months, driving the full year revenue figure. However, current and potential further developments in law, public policy, international trade, and public sentiment as they continue to evolve could further negatively impact our anticipated COVID-19 vaccine revenues and expenses. Inventory write-downs and other charges are estimated to be ~15% of BioNTech’s share of gross profit from COVID-19 vaccines sales in Pfizer’s territory. Anticipated revenues from a pandemic preparedness contract with the German government, from collaborations and from the BioNTech Group service businesses.

4 Strategic Outlook Ryan Richardson, Chief Strategy Officer

27 Partnered with: 1. DualityBio; 2. Bristol Myers Squibb; 3. Pfizer. Strategic Priority Areas in 2025 mRNA cancer immunotherapy BNT327 PD-L1xVEGF bispecific2 Oncology commercial readiness COVID-19 vaccine3 » Expect first randomized data in the adjuvant setting (CRC) in late 2025 or early 2026 » Continue to execute 6 ongoing Phase 2 trials and first novel combination trials » Maximizing potential with global co-development and co- commercialization partnership with BMS » Generate first BNT3272+ ADC combination datasets » Advance BNT323/DB-13031 towards BLA submission » Continue to build targeted AI-enabled commercialization team in key markets » Maintain global COVID-19 vaccine market leadership » Advance next-gen and combination vaccine programs 2025

Save the date Innovation Series: AI Day October 1, 2025 London, UK Innovation Series R&D Day November 11, 2025 New York, NY U.S.

31 Partnered with: 1. Bristol Myers Squibb; 2. Genentech, a member of the Roche Group; 3. In collaboration with Regeneron. 4. DualityBio; 5. We plan to share these data at a medical conference in 2026. Selected Pipeline Milestones in 2025 and Beyond Demonstrate Continued Progress Across Priority Programs Program Indication 2025+ Milestone Next-generation immunomodulator BNT3271 1L/2L SCLC Global Phase 2 dose optimization data 1L/2L TNBC Global Phase 2 dose optimization data mRNA cancer immunotherapy Autogene cevumeran (BNT122 / RO7198457)2 ctDNA+ adj. CRC Phase 2 data BNT1113 2L+ melanoma Phase 2 data Targeted therapy BNT323/DB-13034 2L+ HER2 EC Phase 2 data5 Regulatory submission

BioNTech’s Oncology Pipeline – Phase 2 and Phase 3 Clinical Trials Partnered with: 1. Genentech, member of Roche Group; 2. Genmab; 3. MediLink Therapeutics; 4. OncoC4; 5. DualityBio. 6. In collaboration with Regeneron; 7. Trial ongoing in China only. BNT327 (PD-L1 x VEGF-A) 1L/2L met. TNBC, + CTx BNT316/ONC-392 (gotistobart)4 (CTLA-4) aPD-1/PD-L1 experienced squamous NSCLC BNT323/DB-13035 (trastuzumab pamirtecan) (HER2) HR+/HER2-low met. breast cancer BNT1116 aPD-(L)1-R/R melanoma, + cemiplimab Autogene cevumeran (BNT122/RO7198457)1 Adj. ctDNA+ stage II or III CRC BNT1166 1L adv. PD-L1  50% NSCLC, + cemiplimab Autogene cevumeran (BNT122/RO7198457)1 Adj. PDAC, + atezolizumab + mFOLFIRINOX BNT316/ONC-392 (gotistobart)4 PROC, + pembrolizumab BNT327 (PD-L1 x VEGF-A) 1L/2L+ (ES-)SCLC, + CTx Autogene cevumeran (BNT122/RO7198457)1 Adj. MIUC, + nivolumab BNT327 (PD-L1 x VEGF-A) 2L SCLC, + CTx7 BNT327 (PD-L1 x VEGF-A) 2L ES-SCLC, + CTx7 BNT327 (PD-L1 x VEGF-A) 1L ES-SCLC + CTx7 BNT327 (PD-L1 x VEGF-A) EGFR TKI experienced, EGFRm NSCLC, + CTx7 BNT327 (PD-L1 x VEGF-A) 1L MPM, + CTx7 BNT327 (PD-L1 x VEGF-A) 1L HCC + CTx7 BNT327 (PD-L1 x VEGF-A) 1L TNBC, + CTx7 Phase 3Phase 2 mRNA immunotherapy Next generation IO Targeted therapy BNT327 (PD-L1 x VEGF-A) 1L SCLC, + CTx BNT327 (PD-L1 x VEGF-A) 1L NSCLC, + CTx BNT327 (PD-L1 x VEGF-A) 1L TNBC, + CTx PLANNED BNT323/DB-13035 (trastuzumab pamirtecan) (HER2) HER2+ endometrial cancer PLANNEDBNT327 (PD-L1 x VEGF-A) 2L NEN, + CTx7 BNT323/DB-13035 (trastuzumab pamirtecan) (HER2), multiple solid tumors 32 BNT327 (PD-L1 x VEGF-A) 2L NSCLC, + CTx BNT327 or BNT325/DB-1305 + BNT324/DB-13116 combination Multiple solid tumors BNT113 1L rel./met. HPV16+ PD-L-1+ HNC, + pembrolizumab

BioNTech’s Oncology Pipeline – Phase 1 and Phase 1/2 Clinical Trials Partnered with: 1. Genentech, member of Roche Group; 2. Genmab; 3. In collaboration with Regeneron; 4. MediLink Therapeutics; 5. OncoC4; 6. DualityBio. 7. Trial ongoing in China only. Phase 1/2Phase 1 BNT211 (CLDN6) Multiple solid tumors BNT312/GEN10422 (CD40x4-1BB) Multiple solid tumors BNT316/ONC-392 (gotistobart)5 (CTLA-4) Multiple solid tumors BNT325/DB-13056 (TROP2) Multiple solid tumors BNT324/DB-13116 (B7-H3) Multiple solid tumors BNT116 Adv. NSCLC BNT314/GEN10592 (EpCAMx4-1BB) Multiple solid tumors BNT326/YL2024 (HER3) Multiple solid tumors BNT327 + BNT325/DB-13056 combination Multiple solid tumors BNT327 (PD-L1 x VEGF-A) 1L TNBC7 BNT327 (PD-L1 x VEGF-A) Multiple solid tumors7 BNT152 + BNT153 (IL-7, IL-2) Multiple solid tumors BNT327 + BNT3213 combination 1L HCC7 BNT317 Multiple solid tumors BNT327 + BNT323/DB-13036 (trastuzumab pamirtecan) combination Adv. or metastatic breast cancer BNT327 + BNT324/DB-13116 combination Adv. or metastatic NSCLC or SCLC BNT327 + BNT326/YL2024 combination Multiple solid tumors PLANNED Autogene cevumeran (BNT122/RO7198457)1 Multiple solid tumors 33 mRNA immunotherapy Next generation IO Targeted therapy BNT316/ONC-392 (gotistobart)5 (CTLA-4) mCRPC, + radiotherapy BNT327 + BNT314/GEN10592 combination Advanced CRC PLANNED

Abbreviation Directory n L nth line FixVac Fixed Antigen Vaccine PDAC Pancreatic ductal adenocarcinoma AACR American Association for Cancer Research FPD First patient dosed PD-(L)1 Programmed cell death protein (ligand) 1 ADC Antibody-drug conjugate HCC Hepatocellular carcinoma PFS Progression-free survival adj. Adjuvant HER2 (or 3) Human epidermal growth factor receptor 2 (or 3) PFS Prefilled Syringes AI Artificial intelligence HNSCC Head and neck squamous cell carcinoma PR Partial response AIOM Associazione Italiana di Oncologia Medica HPV Human papilloma virus PROC Platinum-resistant ovarian cancer ALK Anaplastic large-cell lymphoma kinase HR Hormone receptor PVRIG Poliovirus receptor-related immunoglobulin AST Aspartate aminotransferase IHC Immunohistochemistry QxW Every x week(s) ASCO American Society of Clinical Oncology IL-x Interleukin x R&D Research and development B7-H3 Also known as CD276 iNeST Individualized NeoAntigen-Specific Therapy R/R Relapsed/refractory BC Breast cancer IO Immuno-oncology SABCS San Antonio Breast Cancer Symposium BLA Biologics License Applications ITT Intention to treat (ES)SCLC (Extensive stage) small cell lung cancer bsAb Bispecific antibody M&A Merger and acquisitions SD Stable disease CD-x Cluster of differentiation MAGE-A3 Melanoma antigen A3 SDV Single dose vial CI Confidence interval MDV Multi dose vial SEC U.S. Securities and Exchange Commission CLDN6 Claudin 6 met Metastatic SEER Surveillance, epidemiology, and end results CPS Combined positive score MIUC Muscle-invasive urothelial carcinoma SG&A Selling, general and administrative expenses CRC Colorectal cancer MOA Mechanism of Action TIGIT T cell immunoreceptor with Ig and ITIM domains CRPC Castration resistant prostate cancer MPM Malignant pleural mesothelioma TKI Tyrosine kinase inhibitor ctDNA Circulating tumor DNA mRNA Messenger ribonucleic acid TME Tumor microenvironment CTLA4 Cytotoxic T-lymphocyte-associated protein 4 NCT National clinical trial TNBC Triple-negative breast cancer CTx Chemotherapy NEN Neuroendocrine neoplasm TRAE Treatment-related adverse event DCR Disease control rate NME New molecular entity TROP2 Trophoblast cell-surface antigen 2 EC Endometrial cancer NSCLC Non-small cell lung cancer UTI Urinary tract infection EGFR Epidermal growth factor receptor NY-ESO-1 New York esophageal squamous cell carcinoma-1 VEGF-A Vascular endothelial growth factor A ELCC European Lung Cancer Congress ORR Objective response rate VHH Heavy chain variable EpCAM Epithelial cell adhesion molecule OS Overall survival WBC White blood cell ESMO European Society for Medical Oncology OX40 CD134 WCLC World Conference of Lung Cancer Fab Fragment antigen binding P&L Profit and loss statement WT Wild type FDA U.S. Food and Drug Administration PD Progressive disease 34